华峰制药品牌怎么样 申请店铺

我要投票 华峰制药在医疗器械行业中的票数:160 更新时间:2025-04-11
华峰制药是哪个国家的品牌?「华峰制药」是 河南华峰制药有限公司 旗下著名品牌。该品牌发源于河南省濮阳市,由创始人娄 *在2000年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力华峰制药品牌出海!通过在本页面挂载华峰制药品牌的产品链接和联系邮箱,可以提高华峰制药产品曝光!跨境电商爆单神器,目前只要100元/年哦~

华峰制药怎么样

河南华峰制药有限公司是2000年5月经国家有关部委批准成立的股份制企业,现有资产5000万元, 厂区占地面积3万平方米,建筑面积2万平方米,占地62亩的二期工程正在筹建中。公司拥有各类高、中级技术人员200余人,专业营销人员100余人。公司地处园林城、卫生城、文明城、旅游城濮阳市高新技术产业开发区。西有濮阳的绿色庄园、濮上园等城市标志性旅游景点,东临南北走向的城市绿化森林,环境幽雅,交通便利 。

河南华峰制药有限公司以开发治疗骨病系列药品为主,承担着国家治疗骨病骨伤研发药品的项目,目前拥有生产国药准字号丸剂、酒剂及膏药等六个剂型共20多个品种, 形成了具有传统中医药生产销售与临床推广为一体的经营新格局,公司以开发骨病治疗药品为主,承担着国家治疗骨病研究的项目,公司自行研制生产的“娄峰”牌正骨膏、治伤消瘀丸、风湿骨病丸、祛风湿膏、骨痛药酒等,以其品质及适应性赢得了广大用户的认可,在医院专科专病建设领域树立了品牌。公司产品市场销售及医疗服务网络涉及东北地区、北京、山东、山西、安徽、江苏、上海等省市700多家医疗单位,创出了一条医疗服务和药品销售相结合的经营新模式,形成了区域拓展广阔的销售网络。

华峰公司将发展领域定位于人类健康产业,即中医药产业。专注于骨科病等病症的名优中成药,实施名牌战略,中药现代化和产业化的接轨,高度重视以市场为导向,具有前沿技术的研发能力的培育,完善以顾客为导向的营销战略,保障在行业中保持优势的竞争地位。华峰核心竞争力源于企业核心技术能力、应变能力、组织协调能力和企业影响力。华峰注重企业文化的建设借以形成能力出众、卓识创新的人才群体,打造高水准的华峰营销模式,不断改进华峰的管理和生产模式,提高华峰品质,以形成华峰的市场竞争力。

进入新世纪,经济全球化、全球信息化、知识经济新时代已经来临,它对公司现有的生产方式、生活方式、思维方式、管理方式等都将产生重大影响,必将引发企业管理上的新一轮创新性的革命。华峰全体员工将认清形势,持续不断地开展观念创新、知识创新、管理创新、市场创新、机制创新、技术创新、质量创新、产品创新,以求真、务实、创新的精神和干劲,保持企业稳健、持续发展,做行业先锋,创世纪品牌。

成熟的技术,优良的设备,科学的管理,使河南华峰制药有限公司成为研发与生产治疗骨病系列药品的优势企业,在全国地区的中药制药现代化进程中焕发出无限生机。


Henan Huafeng Pharmaceutical Co., Ltd. is a joint-stock enterprise established in May 2000 with the approval of the relevant ministries and commissions of the state. The current assets are 50 million yuan, the plant covers an area of 30000 square meters, the building area is 20000 square meters, and the second phase project covering 62 Mu is under preparation. The company has more than 200 high and intermediate technical personnel and more than 100 professional marketing personnel. The company is located in the park city, health city, civilization city, tourism city Puyang high tech Industrial Development Zone. In the west, there are the Green Manor of Puyang, the park of pushangyuan and other urban landmark tourist attractions. In the East, there is the North-South urban green forest, with elegant environment and convenient transportation. Henan Huafeng Pharmaceutical Co., Ltd. is mainly engaged in the development of a series of drugs for the treatment of osteopathy, and undertakes the national research and development of drugs for the treatment of osteopathy and osteopathy. At present, it has produced more than 20 varieties of six dosage forms, such as Guoyao Zhun brand pills, liquors and plasters, forming a new business pattern with the integration of traditional Chinese medicine production and sales and clinical promotion. The company focuses on the development of drugs for the treatment of osteopathy The company has undertaken the national research project of bone disease treatment. The company has developed and produced "Loufeng" brand bone paste, zhishangxiaoyu pill, Fengshi bone disease pill, Qufengshi ointment, bone pain medicine liquor, etc., which have won the recognition of the majority of users for their quality and adaptability, and established a brand in the field of hospital specialized disease construction. The company's product market sales and medical service network involve more than 700 medical units in Northeast China, Beijing, Shandong, Shanxi, Anhui, Jiangsu, Shanghai and other provinces and cities. It has created a new business model combining medical service and drug sales, and formed a wide regional sales network. Huafeng company will focus on the development of human health industry, that is, traditional Chinese medicine industry. Focus on famous and excellent Chinese patent medicines for orthopedic diseases, implement the famous brand strategy, integrate the modernization and industrialization of traditional Chinese medicine, attach great importance to the cultivation of market-oriented, cutting-edge technology research and development ability, improve customer-oriented marketing strategy, and ensure the competitive position in the industry. The core competitiveness of Huafeng comes from the core technology ability, adaptability, organization and coordination ability and enterprise influence. Huafeng attaches great importance to the construction of corporate culture so as to form a talent group with outstanding ability and outstanding innovation, build a high-level marketing mode, constantly improve the management and production mode of Huafeng, improve the quality of Huafeng, and form the market competitiveness of Huafeng. In the new century, the new era of economic globalization, global information and knowledge economy has come. It will have a significant impact on the company's existing production mode, life style, thinking mode, management mode, etc., and will inevitably lead to a new round of innovative revolution in enterprise management. All staff of Huafeng will recognize the situation, continuously carry out concept innovation, knowledge innovation, management innovation, market innovation, mechanism innovation, technology innovation, quality innovation and product innovation, keep the enterprise steady and sustainable development, be the industry leader and create century brand with the spirit and drive of truth-seeking, pragmatic and innovation. With mature technology, excellent equipment and scientific management, Henan Huafeng Pharmaceutical Co., Ltd. has become an advantageous enterprise in R & D and production of series drugs for treating bone disease, which is full of infinite vitality in the process of modernization of traditional Chinese medicine in the whole country.

本文链接: https://brand.waitui.com/e4731c9c9.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

上海医药李永忠:2025年是上药控股AI及新零售双元年

36氪获悉,4月10日,“上药新零售·智链未来创新生态圈峰会”在沪举行。上海医药执行董事兼执行总裁李永忠表示,2025年是上药控股AI及新零售双元年,期待与更多志同道合的伙伴共同把握院外市场机遇,着力构建新零售产业协同网络。上药控股零售业务总监、上药云健康董事长李志刚正式发布“上药新零售一体化战略”。他指出,依托上药覆盖近1500家门店的零售网络,以及成熟的供应链体系,将继续提升新零售战略能级,推进创新药体系及批零协同等大零售体系建设。

8分钟前

长飞光纤:拟以1.6亿元至3.2亿元回购股份

36氪获悉,长飞光纤公告,公司拟以不低于1.6亿元且不超过3.2亿元的自有资金,通过集中竞价交易方式回购A股股份,用于员工持股计划。回购价格不超过57.53元/股,回购期限为自董事会审议通过之日起12个月。

8分钟前

威腾电气:拟与深度湾、上海磐星设立合资公司 开展高速光模块/组等光通信产品业务

36氪获悉,威腾电气公告,公司拟与上海深度湾科技、上海磐星企业管理合伙企业(有限合伙)共同投资设立“上海威璞芯光科技有限公司”,注册资本3000万元,其中公司以自有资金出资1530万元,占合资公司注册资本的比例为51%。合资公司将开展基于硅光技术和工艺的高速光模块/组等光通信产品的研发、生产、销售及应用。

8分钟前

国信证券:发行股份购买资产暨关联交易相关申请事项获得受理

36氪获悉,国信证券公告,公司于2025年4月10日收到深圳证券交易所出具的《关于受理国信证券股份有限公司发行股份购买资产申请文件的通知》,深圳证券交易所对公司报送的发行股份购买资产暨关联交易申请文件进行了核对,认为申请文件齐备,决定予以受理。同时,中国证监会就本次交易涉及的万和证券股份有限公司变更主要股东等事项的行政许可申请依法予以受理。本次交易尚需深圳证券交易所审核通过、中国证监会同意注册以及股东变更等事项经过中国证监会有关部门核准后方可正式实施。

8分钟前

欧洲央行管委维勒鲁瓦:特朗普的经济和金融议程是错误的道路

据报道,欧洲央行管委维勒鲁瓦表示,特朗普的经济和金融议程是错误的道路。(第一财经)

8分钟前

本页详细列出关于仁和可立克的品牌信息,含品牌所属公司介绍,仁和可立克所处行业的品牌地位及优势。
咨询